Abstract：Objective To explore the application value of hormone replacement therapy in patients with perimenopausal syndrome.Methods A total of 80 women with perimenopausal syndrome admitted in our hospital from November 2017 to January 2019 were selected as subjects.According to the random number table method, they were divided into observation group (40 cases) and control group (40 cases).Patients in the control group were given symptomatic support treatment, orally administered with Guweisu Tablets and Kuntai Capsules.Patients in the observation group were treated with Estradiol Valerate Tablets combination with Medroxyprogesterone Acetate Dispersive Tablets.Patients in both groups were treated continuously for 6 courses of treatment, as one treatment cycle.After 1 cycle of treatment, all participants were followed up in the outpatient department for 3 months.The scores of female sexual life quality standard indicator scale (FSFI) at 3 months after intervention were compared between the two groups.Changes in levels of sex hormones, such as estradiol (E2), follicle-stimulating hormone (FSH) and luteinizing hormone (LH), at 3 months after intervention were compared between the two groups.The incidence of clinical symptoms such as irritability, fatigue, insomnia, abnormal sex life and hot flashes during the follow-up of the two groups were calculated.The changes of total cholesterol levels before and after intervention were compared between the two groups.Results Three months after intervention, FSFI scores and total score of the observation group were higher than those of the control group, with statistically significant differences (P＜0.05).Three months after intervention, the E2 level of the observation group was higher than that of the control group, and the LH and FSH levels were lower than those of the control group, with statistically significant differences (P＜0.05).During the follow-up, the incidences of clinical symptoms such as irritability, fatigue,insomnia, abnormal sex life and hot flashes in the observation group were all lower than those in the control group, with statistically significant differences (P＜0.05).At 1 and 3 months after intervention, the total cholesterol level of the two groups was lower than that before the intervention, and the total cholesterol level of the observation group was lower than that of the control group, with statistically significant differences (P＜0.05).Conclusion For perimenopausal syndrome, the combination of Estradiol Valerate Tablets with Medroxyprogesterone Acetate Dispersive Tablets can effectively improve the quality of patients' sex life, regulate the level of sex hormones, improve clinical symptoms, and reduce the level of blood lipid.
京公网安备 11010502046607号